Home About us Editorial board Ahead of print Browse Articles Search Submit article Instructions Subscribe Contacts Login 
  • Users Online: 498
  • Home
  • Print this page
  • Email this page

    Article Cited by others

REVIEW ARTICLE

Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence

Etemadifar Masoud, Salari Mehri, Mirmosayyeb Omid, Serati Mehdi, Nikkhah Roham, Askari Mozhde, Fayyazi Emad

Year : 2017| Volume: 22| Issue : 1 | Page no: 18-18

   This article has been cited by
 
1 Retrospective Observation of Low-Dose Rituximab Treatment in Chinese Patients With Neuromyelitis Optica Spectrum Disorders in a Real-World Setting
Haibing Xiao,Wenshuang Zeng,Ling Li,Lina Li,Yuzhen Cui,Jie Wang,Jinhao Ye,Qingyan Yang
Frontiers in Neurology. 2020; 11
[Pubmed]  [Google Scholar] [DOI]
2 Proteomic profiles of major serum proteins in seropositive NMO patients alter after Rituximab treatment
Suparna Saha,Soumava Mukherjee,Gautam Guha,Debashis Mukhopadhyay
Journal of Proteins and Proteomics. 2020;
[Pubmed]  [Google Scholar] [DOI]
3 Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models
Yan Wu,Lianmei Zhong,Jia Geng
Multiple Sclerosis and Related Disorders. 2019; 27: 412
[Pubmed]  [Google Scholar] [DOI]
4 Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study
V. Shaygannejad,E. Fayyazi,S. Badihian,O. Mirmosayyeb,N. Manouchehri,F. Ashtari,N. Asgari
Journal of Neurology. 2019;
[Pubmed]  [Google Scholar] [DOI]
5 Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis
Wenjuan Huang,Liang Wang,Baojingzi Zhang,Lei Zhou,Tiansong Zhang,Chao Quan
Multiple Sclerosis and Related Disorders. 2019;
[Pubmed]  [Google Scholar] [DOI]
6 Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder
V. T. W. Chang,H.-M. Chang
Neuropathology and Applied Neurobiology. 2019;
[Pubmed]  [Google Scholar] [DOI]
7 Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city
Fereshteh Ashtari,Roshanak Mehdipour,Vahid Shaygannejad,Marjan Mansourian
Multiple Sclerosis and Related Disorders. 2019; 34: 77
[Pubmed]  [Google Scholar] [DOI]
8 B-cell Therapy for Multiple Sclerosis: Entering an era
Ariele L. Greenfield,Stephen L. Hauser
Annals of Neurology. 2018; 83(1): 13
[Pubmed]  [Google Scholar] [DOI]
9 Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab
K Shidahara,K Hayashi,K E Sada,S Hiramatsu,M Morishita,H Watanabe,Y Matsumoto,T Kawabata,J Wada
Lupus. 2018; 27(8): 1374
[Pubmed]  [Google Scholar] [DOI]
10 Rituximab before and during pregnancy
Gitanjali Das,Vincent Damotte,Jeffrey M. Gelfand,Carolyn Bevan,Bruce A.C. Cree,Lynn Do,Ari J. Green,Stephen L. Hauser,Riley Bove
Neurology - Neuroimmunology Neuroinflammation. 2018; 5(3): e453
[Pubmed]  [Google Scholar] [DOI]
11 Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders
Andrea MarcinnÚ,Fabiana Marnetto,Paola Valentino,Serena Martire,Alessia Balbo,Aurora Drago,Maria Leto,Marco Capobianco,Giancarlo Panzica,Antonio Bertolotto
Neurology - Neuroimmunology Neuroinflammation. 2018; 5(6): e498
[Pubmed]  [Google Scholar] [DOI]
12 The link between morphology and complement in ocular disease
Camilla Mohlin,Kerstin Sandholm,Kristina N. Ekdahl,Bo Nilsson
Molecular Immunology. 2017;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article